World journal of surgical oncology · 2014
Goserelin plus endocrine treatments maintained long-term clinical benefit in a male patient with advanced breast cancer.
Клинический случайСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Jiang Hang, Wang Tao, Jiang Zefei
Аннотация
BACKGROUND: Goserelin plus aromatase inhibitors (AI) have already been used in male advanced breast cancer, but the cases that fulvestrantin male breast cancer are rare.
CASE PRESENTATION: Here we report a case of long-term (3 years) response to Goserelin plus continuing endocrine treatments given for a male advanced breast cancer. The patient prolongs his life with high life quality, and has more time with his family.
CONCLUSION: Goserelin plus endocrine treatments may benefit male breast cancer.
CASE PRESENTATION: Here we report a case of long-term (3 years) response to Goserelin plus continuing endocrine treatments given for a male advanced breast cancer. The patient prolongs his life with high life quality, and has more time with his family.
CONCLUSION: Goserelin plus endocrine treatments may benefit male breast cancer.